Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins.

Patrizia Cancemi, Gabriella Schiera, Italia Di Liegro, Carlo Maria Di Liegro, Anna Fricano, Gianluca Di Cara, Anna Fricano, Oriana Colletta, Veronica Puleo, Gabriella Schiera, Patrizia Cancemi, Carlo Maria Di Liegro

Risultato della ricerca: Article

13 Citazioni (Scopus)

Abstract

Extracellular vesicles (EVs) are now recognized as a fundamental way for cell-to-cell horizontal transfer of properties, in both physiological and pathological conditions. Most of EV-mediated cross-talk among cells depend on the exchange of proteins, and nucleic acids, among which mRNAs, and non-coding RNAs such as different species of miRNAs. Cancer cells, in particular, use EVs to discard molecules which could be dangerous to them (for example differentiation-inducing proteins such as histone H1.0, or antitumor drugs), to transfer molecules which, after entering the surrounding cells, are able to transform their phenotype, and even to secrete factors, which allow escaping from immune surveillance. Herein we report that melanoma cells not only secrete EVs which contain a modified form of H1.0 histone, but also transport the corresponding mRNA. Given the already known role in tumorigenesis of some RNA binding proteins (RBPs), we also searched for proteins of this class in EVs. This study revealed the presence in A375 melanoma cells of at least three RBPs, with apparent MW of about 65, 45 and 38 kDa, which are able to bind H1.0 mRNA. Moreover, we purified one of these proteins, which by MALDI-TOF mass spectrometry was identified as the already known transcription factor MYEF2.
Lingua originaleEnglish
pagine (da-a)1807-1814
Numero di pagine8
RivistaInternational Journal of Oncology
Volume49
Stato di pubblicazionePublished - 2016

Fingerprint

Histones
Melanoma
Carrier Proteins
Messenger RNA
RNA-Binding Proteins
Proteins
Untranslated RNA
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Extracellular Vesicles
MicroRNAs
Antineoplastic Agents
Nucleic Acids
Mass Spectrometry
Carcinogenesis
Transcription Factors
Phenotype
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins. / Cancemi, Patrizia; Schiera, Gabriella; Di Liegro, Italia; Di Liegro, Carlo Maria; Fricano, Anna; Di Cara, Gianluca; Fricano, Anna; Colletta, Oriana; Puleo, Veronica; Schiera, Gabriella; Cancemi, Patrizia; Di Liegro, Carlo Maria.

In: International Journal of Oncology, Vol. 49, 2016, pag. 1807-1814.

Risultato della ricerca: Article

Cancemi, Patrizia ; Schiera, Gabriella ; Di Liegro, Italia ; Di Liegro, Carlo Maria ; Fricano, Anna ; Di Cara, Gianluca ; Fricano, Anna ; Colletta, Oriana ; Puleo, Veronica ; Schiera, Gabriella ; Cancemi, Patrizia ; Di Liegro, Carlo Maria. / Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins. In: International Journal of Oncology. 2016 ; Vol. 49. pagg. 1807-1814.
@article{e6bd90880ea646d9bfc8fb10bf610a36,
title = "Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins.",
abstract = "Extracellular vesicles (EVs) are now recognized as a fundamental way for cell-to-cell horizontal transfer of properties, in both physiological and pathological conditions. Most of EV-mediated cross-talk among cells depend on the exchange of proteins, and nucleic acids, among which mRNAs, and non-coding RNAs such as different species of miRNAs. Cancer cells, in particular, use EVs to discard molecules which could be dangerous to them (for example differentiation-inducing proteins such as histone H1.0, or antitumor drugs), to transfer molecules which, after entering the surrounding cells, are able to transform their phenotype, and even to secrete factors, which allow escaping from immune surveillance. Herein we report that melanoma cells not only secrete EVs which contain a modified form of H1.0 histone, but also transport the corresponding mRNA. Given the already known role in tumorigenesis of some RNA binding proteins (RBPs), we also searched for proteins of this class in EVs. This study revealed the presence in A375 melanoma cells of at least three RBPs, with apparent MW of about 65, 45 and 38 kDa, which are able to bind H1.0 mRNA. Moreover, we purified one of these proteins, which by MALDI-TOF mass spectrometry was identified as the already known transcription factor MYEF2.",
author = "Patrizia Cancemi and Gabriella Schiera and {Di Liegro}, Italia and {Di Liegro}, {Carlo Maria} and Anna Fricano and {Di Cara}, Gianluca and Anna Fricano and Oriana Colletta and Veronica Puleo and Gabriella Schiera and Patrizia Cancemi and {Di Liegro}, {Carlo Maria}",
year = "2016",
language = "English",
volume = "49",
pages = "1807--1814",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",

}

TY - JOUR

T1 - Extracellular vesicles shed by melanoma cells contain a modified form of H1.0 linker histone and H1.0 mRNA-binding proteins.

AU - Cancemi, Patrizia

AU - Schiera, Gabriella

AU - Di Liegro, Italia

AU - Di Liegro, Carlo Maria

AU - Fricano, Anna

AU - Di Cara, Gianluca

AU - Fricano, Anna

AU - Colletta, Oriana

AU - Puleo, Veronica

AU - Schiera, Gabriella

AU - Cancemi, Patrizia

AU - Di Liegro, Carlo Maria

PY - 2016

Y1 - 2016

N2 - Extracellular vesicles (EVs) are now recognized as a fundamental way for cell-to-cell horizontal transfer of properties, in both physiological and pathological conditions. Most of EV-mediated cross-talk among cells depend on the exchange of proteins, and nucleic acids, among which mRNAs, and non-coding RNAs such as different species of miRNAs. Cancer cells, in particular, use EVs to discard molecules which could be dangerous to them (for example differentiation-inducing proteins such as histone H1.0, or antitumor drugs), to transfer molecules which, after entering the surrounding cells, are able to transform their phenotype, and even to secrete factors, which allow escaping from immune surveillance. Herein we report that melanoma cells not only secrete EVs which contain a modified form of H1.0 histone, but also transport the corresponding mRNA. Given the already known role in tumorigenesis of some RNA binding proteins (RBPs), we also searched for proteins of this class in EVs. This study revealed the presence in A375 melanoma cells of at least three RBPs, with apparent MW of about 65, 45 and 38 kDa, which are able to bind H1.0 mRNA. Moreover, we purified one of these proteins, which by MALDI-TOF mass spectrometry was identified as the already known transcription factor MYEF2.

AB - Extracellular vesicles (EVs) are now recognized as a fundamental way for cell-to-cell horizontal transfer of properties, in both physiological and pathological conditions. Most of EV-mediated cross-talk among cells depend on the exchange of proteins, and nucleic acids, among which mRNAs, and non-coding RNAs such as different species of miRNAs. Cancer cells, in particular, use EVs to discard molecules which could be dangerous to them (for example differentiation-inducing proteins such as histone H1.0, or antitumor drugs), to transfer molecules which, after entering the surrounding cells, are able to transform their phenotype, and even to secrete factors, which allow escaping from immune surveillance. Herein we report that melanoma cells not only secrete EVs which contain a modified form of H1.0 histone, but also transport the corresponding mRNA. Given the already known role in tumorigenesis of some RNA binding proteins (RBPs), we also searched for proteins of this class in EVs. This study revealed the presence in A375 melanoma cells of at least three RBPs, with apparent MW of about 65, 45 and 38 kDa, which are able to bind H1.0 mRNA. Moreover, we purified one of these proteins, which by MALDI-TOF mass spectrometry was identified as the already known transcription factor MYEF2.

UR - http://hdl.handle.net/10447/207776

UR - https://www.spandidos-publications.com/10.3892/ijo.2016.3692

M3 - Article

VL - 49

SP - 1807

EP - 1814

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

ER -